Konruns(SH:603590) Xin Lang Cai Jing·2025-11-13 02:54Core Viewpoint - Kangchen Pharmaceutical's stock has shown significant growth this year, with a year-to-date increase of 105.40%, despite recent fluctuations in the short term [2]. Financial Performance - For the period from January to September 2025, Kangchen Pharmaceutical achieved a revenue of 6.92 billion yuan, representing a year-on-year growth of 7.10%. The net profit attributable to the parent company was 1.28 billion yuan, reflecting a year-on-year increase of 13.19% [2]. - The company has distributed a total of 4.37 billion yuan in dividends since its A-share listing, with 1.75 billion yuan distributed over the past three years [3]. Stock Market Activity - As of November 13, Kangchen Pharmaceutical's stock price was 47.08 yuan per share, with a market capitalization of 75.03 billion yuan. The stock experienced a 2.06% increase during the trading session [1]. - The stock has been active on the龙虎榜 (top trading list) four times this year, with the most recent appearance on September 1 [2]. Shareholder Structure - As of September 30, 2025, the number of shareholders increased to 10,700, up by 7.18% from the previous period. The average number of circulating shares per shareholder decreased by 6.12% to 14,806 shares [2]. - New institutional shareholders include several funds, such as Qianhai Kaiyuan and Huatai-PineBridge, which have recently entered the top ten circulating shareholders list [3].